Wednesday, October 8, 2025

Latest

Khiron Enters Exclusive Agreement With Brazilian Pharmaceutical Distributor

Khiron Life Sciences (TSXV: KHRN) announced after market close yesterday that it had entered into an exclusive agreement with that of Medlive, a Brazil-based pharmaceutical and health products distributor with a network of over 3,000 hospitals and clinics in Souther Brazil.

The exclusive agreement will see Medlive distribute Khiron’s medical cannabis products throughout its network of doctors office, clinics, government institutions, pharmacies and hospitals. To further increase sales of Khiron’s products, the two companies will also embark on a medical education and training initiative with practitioners in Medlive’s network to increase the awareness of Khiron’s products while also pushing the health benefits that they offer. This initiative is to begin in the third quarter of 2020.

“Brazil represents one of the most important markets in Latin America, with its massive population and its acceptance of medical cannabis. Together with Medlive we are now positioned to begin educating health professionals and driving prescriptions for our medical cannabis products, and ultimately focus on our objective to help patients in Brazil who can benefit from medical cannabis. Medlive is recognized as an important medical marketing organization in the region and we could not have a better partner to help us achieve these goals.”
Alvaro Torres, CEO

Khiron initially received authorization from the Brazilian Health Regulatory Agency to export medical cannabis products to the country on February 7, 2020, which will be conducted on an individual patient-use basis. This authorization is significant, as Brazil represents the largest market in Latin America with a population in excess of 212 million. The medical cannabis market within the country is anticipated to grow to 3.4 million patients, with over 1,100 physicians now prescribing it to patients.

Khiron Life Sciences last traded at $0.61 on the TSX Venture.


FULL DISCLOSURE: Khiron Life Sciences is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Khiron Life Sciences on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Video Articles

Fortune Bay: The Potential Billion Dollar Project

Japan Gold Enters New Chapter as Barrick Alliance Concludes – John Proust

Barrick Mining’s “Company Defining [Gold] Discovery”

Recommended

Nord Precious Metals Produces High Grade Silver Concentrate From Tailings

ESGold Secures $9 Million In Non-Dilutive Funding From Ocean Partners

Related News

Khiron Life Sciences Receives Authorization For The Sale Of High-CBD Medical Cannabis In Peru

Khiron Life Sciences (TSXV: KHRN) announced this morning that it now has access to yet...

Thursday, July 23, 2020, 08:59:43 AM

Khiron Life Sciences Sees CFO Resign, Appoints Third-Party Interim

Khiron Life Sciences Corp. (TSXV: KHRN) announced on Friday after the closing bell that its...

Monday, October 4, 2021, 10:41:00 AM

Khiron To Conduct Live Virtual Tour Of New Medical Facility On July 21

What do you do when your investors are located thousands of miles away from your...

Friday, July 17, 2020, 08:51:42 AM

Khiron Life Sciences Looks To Acquire PharmaDrug’s German Subsidiary For $2.0 Million

Khiron Life Sciences Corp. (TSXV: KHRN) announced today the plan to acquire Pharmadrug GmbH, a...

Tuesday, May 31, 2022, 10:34:00 AM

Khiron Life Sciences Conducts Bought Deal Financing For Gross Proceeds Of $10.0 Million

Khiron Life Sciences (TSXV: KHRN) announced that it is conducting at $10.0 bought deal private...

Monday, November 9, 2020, 08:43:24 AM